
Novartis has revealed that its arthritis drug, theinterleukin-1 beta inhibitor canakinumab, in combination with standard of care (SoC), failed to …
The FDA has asked Novartis for more information on its gouty arthritis drug canakinumab. The regulator’s request came in a …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

